Astragalus membranaceus inhibits peritoneal fibrosis via monocyte chemoattractant protein (MCP)-1 and the transforming growth factor-β1 (TGF-β1) pathway in rats submitted to peritoneal dialysis

International Journal of Molecular Sciences

Volumn 15, Issue 7, 2014, Pages 12959-12971

  Li, Zhenghong ^a   Zhang, Lu ^a   He, Weiming ^a   Zhu, Changle ^a   Yang, Jinsong ^a   Sheng, Meixiao ^a  

^a THE FIRST AFFILIATED HOSPITAL OF NANJING MEDICAL UNIVERSITY   (China)

Author keywords

Astragalus membranaceus; Monocyte chemoattractant protein; Peritoneal dialysis; Peritoneal fibrosis; Transforming growth factor 1

Indexed keywords

ASTRAGALUS MEMBRANACEUS EXTRACT; COLLAGEN TYPE 3; DIALYSIS FLUID; FIBROBLAST SURFACE PROTEIN; MESSENGER RNA; MONOCYTE CHEMOTACTIC PROTEIN 1; PEPTIDES AND PROTEINS; SMAD2 PROTEIN; SMAD3 PROTEIN; TRANSFORMING GROWTH FACTOR BETA1; TUMOR NECROSIS FACTOR ALPHA; UNCLASSIFIED DRUG; PLANT EXTRACT;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTIFIBROTIC ACTIVITY; ANTIINFLAMMATORY ACTIVITY; ARTICLE; CELL ACTIVATION; CONTROLLED STUDY; DRUG ACTIVITY; DRUG MEGADOSE; ENZYME LINKED IMMUNOSORBENT ASSAY; IMMUNOHISTOCHEMISTRY; LOW DRUG DOSE; MACROPHAGE; MALE; MEDICAL PARAMETERS; MORPHOLOGY; NONHUMAN; PERITONEAL DIALYSIS; PERITONEAL FIBROSIS; PERITONEUM THICKNESS; PROTEIN EXPRESSION; RAT; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; SIGNAL TRANSDUCTION; ANIMAL; ASTRAGALUS MEMBRANACEUS; CHEMISTRY; CYTOLOGY; GENETICS; METABOLISM; MONOCYTE; PATHOLOGY; PERITONEUM; PHYSIOLOGY; SPRAGUE DAWLEY RAT;

ANIMALS; ASTRAGALUS MEMBRANACEUS; CHEMOKINE CCL2; IMMUNOHISTOCHEMISTRY; MACROPHAGES; MALE; MONOCYTES; PERITONEAL DIALYSIS; PERITONEAL FIBROSIS; PERITONEUM; PLANT EXTRACTS; RATS; RATS, SPRAGUE-DAWLEY; RNA, MESSENGER; SIGNAL TRANSDUCTION; SMAD2 PROTEIN; SMAD3 PROTEIN; TRANSFORMING GROWTH FACTOR BETA1;

EID: 84904666219     PISSN: 16616596     EISSN: 14220067     Source Type: Journal    
DOI: 10.3390/ijms150712959     Document Type: Article

References (37)

1. Burkart, J.M. Peritoneal dialysis should be considered as the first line of renal replacement therapy for most ESRD patients. Blood Purif. 2001, 19, 179-184.
2. Chaudhary, K.; Sangha, H.; Khanna, R. Peritoneal dialysis first: Rationale. Clin. J. Am. Soc. Nephrol. 2011, 6, 447-456.
3. Bradley, J.A.; Hamilton, D.N.; McWhinnie, D.L.; Briggs, J.D.; Junor, B.J. Sclerosing peritonitis after CAPD. Lancet 1983, 2, 572-573.
4. Oreopoulos, D.G.; Khanna, R.; Wu, G. Sclerosing obstructive peritonitis after CAPD. Lancet 1983, 2, 409.
5. Grassmann, A.; Gioberge, S.; Moeller, S.; Brown, G. ESRD patients in 2004: Global overview of patient numbers, treatment modalities and associated trends. Nephrol. Dial. Transplant. 2005, 20, 2587-2593.
6. Strippoli, R.; Benedicto, I.; Perez Lozano, M.L.; Pellinen, T.; Sandoval, P.; Lopez-Cabrera, M.; del Pozo, M.A. Inhibition of transforming growthfactor-activated kinase 1 (TAK1) blocks and reverses epithelial to mesenchymaltransition of mesothelial cells. PLoS One 2012, 7, e31492.
7. Strippoli, R.; Benedicto, I.; Foronda, M.; Perez-Lozano, M.L.; Sánchez-Perales, S.; López-Cabrera, M.; del Pozo, M. Á. p38 maintains E-cadherin expression by modulating TAK1-NF-kappa B during epithelial-to-mesenchymal transition. J. Cell Sci. 2010, 123, 4321-4331.
8. Strippoli, R.; Benedicto, I.; Pérez Lozano, M.L.; Cerezo, A.; López-Cabrera, M.; del Pozo, M.A. Epithelial-to-mesenchymal transition of peritoneal mesothelial cells is regulated by an ERK/NF-kappaB/Snail1 pathway. Dis. Model. Mech. 2008, 1, 264-274.
9. Miyazaki, M.; Yuzawa, Y. The role of peritoneal fibrosis in encapsulating peritoneal sclerosis. Perit. Dial. Int. 2005, 25, S48-S56.
10. Mactier, R.A. The spectrum ofperitoneal fibrosing syndromes in peritoneal dialysis. Adv. Perit. Dial. 2000, 16, 223-228.
11. Yanez-Mo, M.; Lara-Pezzi, E.; Selgas, R.; Ramirez-Huesca, M.; Dominguez-Jimenez, C.; Jimenez-Heffernan, J.A. Peritoneal dialysis and epithelial-to-mesenchymal transition of mesothelial cells. N. Engl. J. Med. 2003, 348, 403-413.
12. Margetts, P.J.; Bonniaud, P.; Liu, L.; Hoff, C.M.; Holmes, C.J.; West-Mays, J.A.; Kelly, M.M. Transient overexpression of TGFβ1 induces epithelial mesenchymaltransition in the rodent peritoneum. J. Am. Soc. Nephrol. 2005, 16, 425-436.
13. Devuyst, O.; Margetts, P.J.; Topley, N. The pathophysiology of the peritoneal membrane. J. Am. Soc. Nephrol. 2010, 21, 1077-1085.
14. Goodlad, C.; Brown, E.A. Encapsulating peritoneal sclerosis: What have we learned? Semin. Nephrol. 2011, 31, 183-198.
15. Lv, Z.D.; Na, D.; Ma, X.Y.; Zhao, C.; Zhao, W.J.; Xu, H.M. Human peritoneal mesothelial cell transformation into myofibroblasts in response to TGF-ß1in vitro. Int. J. Mol. Med. 2011, 27, 187-193.
16. Margetts, P.J.; Oh, K.H.; Kolb, M. Transforming growth factor-beta: Importance in long-term peritoneal membrane changes. Perit. Dial. Int. 2005, 25, S15-S17.
17. Gao, J.; Feng, L.J.; Huang, Y.; Li, P.; Xu, D.J.; Li, J.; Wu, Q. Total glucosides of Danggui Buxue Tang attenuates bleomycin-induced pulmonary fibrosis via inhibition ofextracellular matrix remodelling. J. Pharm. Pharmacol. 2012, 64, 811-820.
18. Du, J.X.; Sun, M.Y.; Du, G.L.; Li, F.H.; Liu, C.; Mu, Y.P.; Chen, G.F.; Long, A.H.; Bian, Y.Q.; Liu, J.; et al. Ingredients of Huangqi decoction slow biliary fibrosis progression by inhibiting the activation of the transforming growth factor-beta signaling pathway. BMC Complement. Altern. Med. 2012, 12, 33.
19. Wei, M.G.; Sun, W.; Xiong, P.H.; Shao, J.D. Antifibrotic effect of the Chinese herbs Modified Danggui Buxue Decoction on adriamycin-induced nephropathy in rats. Chin. J. Integr. Med. 2012, 18, 591-598.
20. Huang, W.M.; Liang, Y.Q.; Tang, L.J.; Ding, Y.; Wang, X.H. Antioxidant and anti-inflammatory effects of Astragalus polysaccharideon EA. hy926 cells. Exp. Ther. Med. 2013, 6, 199-203.
21. Lai, P.K.; Chan, J.Y.; Wu, S.B.; Cheng, L.; Ho, G.K.; Lau, C.P.; Kennelly, E.J.; Leung, P.C.; Fung, K.P.; Lau, C.B. Anti-inflammatory activities of an active fraction isolated from the root of Astragalus membranaceusin RAW 264.7 macrophages. Phytother. Res. 2013, 28, 395-404.
22. He, X.; Shu, J.; Xu, L.; Lu, C.; Lu, A. Inhibitory effect of Astragalus polysaccharideson lipopolysaccharide-induced TNF-a and IL-1βproduction in THP-1 cells. Molecules 2012, 17, 3155-3164.
23. Nalbantsoy, A.; Nesil, T.; Yi{dotless}lmaz-Dilsiz, O.; Aksu, G.; Khan, S.; Bedir, E. Evaluation of the immunomodulatory properties in mice andin vitroanti-inflammatory activity of cycloartane type saponins from Astragalusspecies. J. Ethnopharmacol. 2012, 139, 574-581.
24. Kim, B.H.; Oh, I.; Kim, J.H.; Jeon, J.E.; Jeon, B.; Shin, J.; Kim, T.Y. Anti-inflammatory activity of compounds isolated from Astragalus sinicusL. in cytokine-induced keratinocytes and skin. Exp. Mol. Med. 2014, 46, e87.
25. Diao, J.N.; Sheng, M.X.; Zhu, X.X.; Wang, N.J.; Zhu, C.L.; He, W.M. Huangqi (Astragalus membranaceus) injections effect on the dialysis efficiency and structure of peritoneal dialysis rat with high permeable perineum. J. Nanjing TEM Univ. 2011, 27, 58-62. (In Chinese)
26. Von Ruhland, C.J.; Newman, G.R.; Topley, N.; Williams, J.D. Can artifact mimic the pathology of the peritoneal mesothelium? Perit. Dial. Int. 2003, 23, 428-433.
27. Honda, K.; Nitta, K.; Horita, S.; Yumura, W.; Nihei, H. Morphological changes in the peritoneal vasculature of patients on CAPDwith ultrafiltration failure. Nephron 1996, 72, 171-176.
28. Martínez-González, J.; Berrozpe, M.; Varela, O.; Badimon, L. Heterogeneity of smooth muscle cells in advanced human atherosclerotic plaques: Intimal smooth muscle cells expressing a fibroblast surface protein are highly activated by platelet-released products. Eur. J. Clin. Investig. 2001, 31, 939-949.
29. Ely, J.J.; Bishop, M.A.; Lammey, M.L.; Sleeper, M.M.; Steiner, J.M.; Lee, D.R. Use of biomarkers of collagen types I and III fibrosis metabolism to detect cardiovascular and renal disease in chimpanzees (Pan troglodytes). Comp. Med. 2010, 60, 154-158.
30. Chow, F.Y.; Nikolic-Paterson, D.J.; Ozols, E.; Atkins, R.C.; Rollin, B.J.; Tesch, G.H. Monocyte chemoattractant protein-1 promotes the development of diabetic renal injury in streptozotocin-treated mice. Kidney Int. 2006, 69, 73-80.
31. Wada, T.; Furuichi, K.; Sakai, N.; Iwata, Y.; Kitagawa, K.; Ishida, Y.; Kondo, T.; Hashimoto, H.; Ishiwata, Y.; Mukaida, N.; et al. Gene therapy via blockade of monocyte chemoattractant protein-1 for renal fibrosis. J. Am. Soc. Nephrol. 2004, 15, 940-948.
32. Xu, J.; Lin, S.C.; Chen, J.; Miao, Y.; Taffet, G.E.; Entman, M.L.; Wang, Y. CCR2 mediates the uptake of bone marrowderived fibroblast precursors in angiotensin II-induced cardiac fibrosis. Am. J. Physiol. Heart Circ. Physiol. 2011, 301, H538-H547.
33. Lee, S.H.; Kang, H.Y.; Kim, K.S.; Nam, B.Y.; Paeng, J.; Kim, S.; Li, J.J.; Park, J.T.; Kim, D.K.; Han, S.H.; et al. The monocyte chemoattractant protein-1 (MCP-1)/CCR2 system is involved in peritoneal dialysis-related epithelial-mesenchymal transition of peritoneal mesothelial cells. Lab. Investig. 2012, 92, 1698-1711.
34. Yang, Y.; Yang, S.; Chen, M.; Zhang, X.; Zou, Y.; Zhang, X. Compound Astragalusand Salvia miltiorrhizaextract exerts anti-fibrosis by mediating TGF-beta/Smad signaling in myofibroblasts. J. Ethnopharmacol. 2008, 118, 264-270.
35. He, S.; Yang, Y.; Liu, X.; Huang, W.; Zhang, X.; Yang, S.; Zhang, X. Compound Astragalusand Salvia miltiorrhizaextract inhibits cell proliferation, invasion and collagen synthesis in keloid fibroblasts by mediating transforming growth factor-β/Smad pathway. Br. J. Dermatol. 2012, 166, 564-574.
36. Sullivan, D.E.; Ferris, M.; Nguyen, H.; Abboud, E.; Brody, A.R. TNF-alpha induces TGF-beta1 expression in lung fibroblasts at the transcriptional level via AP-1 activation. J. Cell. Mol. Med. 2009, 13, 1866-1876.
37. Musi, B.; Braide, M.; Carlsson, O.; Wieslander, A.; Albrektsson, A.; Ketteler, M.; Westenfeld, R.; Floege, J.; Rippe, B. Biocompatibility of peritoneal dialysis fluids: Long-term exposure of nonuremic rats. Perit. Dial. Int. 2004, 24, 37-47.